This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Armstrong DK , Blessing JA , Look KY , Schilder R , Nunez ER
A randomized phase II evaluation of bryostatin-1 (NSC #339555) in recurrent or persistent platinum-sensitive ovarian cancer: A Gynecologic Oncology Group Study
Investigational New Drugs. 2003 Aug;21(3) :373-377
AbstractObjectives. The Gynecologic Oncology Group (GOG) performed a randomized phase II study to determine the antitumor activity and toxicity of two different schedules of bryostatin-1 administration in patients with recurrent or persistent platinum-sensitive epithelial ovarian cancer or primary peritoneal carcinoma. Methods. Eligible patients were randomized to receive either bryostatin-1 25 mug/m(2) as a 1 h infusion weekly for 3 weeks followed by a 1-week rest (Regimen 1) or bryostatin-1 120 mug/m(2) as a 72 h continuous infusion every 2 weeks (Regimen 11). Results. Fifty- five patients were enrolled on this study. There was one durable response among 27 eligible patients (response rate = 3.7%) on Regimen II and no responses in the 27 eligible patients on Regimen I. Nineteen patients (eleven on Regimen I and eight on Regimen II) had stable disease. The most common adverse event was myalgia, with 12 of 27 patients (44%) on each regimen experiencing some degree of myalgia. There were no other significant toxicities on either treatment arm. Conclusions. Both of these schedules and doses of bryostatin-1 are inactive as single agents in previously treated epithelial ovarian cancer.
NotesArmstrong, DK,Johns Hopkins Oncol Ctr, Dept Obstet & Gynecol, Clin Res Bldg,Room 190,1650 Orleans St, Baltimore, MD 21231 USA Article English